Arbor Biotechnologies is Drug Discovery in United States that focus on high-throughput screening business. Founded in 2016. They cover business area such as developer, transformative therapeutic product, human health, sustainability, a diverse set, technology, technique, artificial intelligence, genome sequencing, gene synthesis, high-throughput screening, protein, medical application.
2016
( 8 years old in 2024 )
High-throughput Screening
-
20 Acorn Park Drive
Tower 500
Cambridge, MA 02140
United States
Private
developertransformative therapeutic producthuman healthsustainabilitya diverse settechnologytechniqueartificial intelligencegenome sequencinggene synthesishigh-throughput screeningproteinmedical application
* We use standard office opening hours in near Arbor Biotechnologies's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Arbor Biotechnologies is Drug Discovery business from United States that founded in 2016 (8 years old in 2024), Arbor Biotechnologies business is focusing on High-throughput Screening.
Arbor Biotechnologies headquarter office and corporate office address is located in 20 Acorn Park Drive Tower 500 Cambridge, MA 02140 United States.
Arbor Biotechnologies was founded in United States.
In 2024, Arbor Biotechnologies is currently focus on high-throughput screening sector.
Above is snippet of Google Trends for "high-throughput screening" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Arbor Biotechnologies, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
